Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0394 • ACR Convergence 2023
Higher Intakes of Red Meat Are Associated with an Increased Risk of Developing Seropositive but Not Seronegative Rheumatoid Arthritis – Results from a Nested Case-Control Study
Rebecka Teresia Bäcklund¹, Isabel Drake¹, Ulf Bergström¹, Michele Compagno², Emily Sonestedt¹ and Carl Turesson¹, ¹Lund University, Malmö, Sweden, ²Lund University, Lund, Sweden
Background/Purpose: Healthy eating habits might prevent the development of rheumatoid arthritis (RA). We aimed to examine the relation between adherence to dietary recommendations and the…
Abstract Number: 0411 • ACR Convergence 2023
The Impact of Patient-reported Outcomes on Boolean 2.0 Remission Criteria in Rheumatoid Arthritis Patients in Real Clinical Practice -a Multicenter Observational Study: T-FLAG Study-
Mochihito Suzuki¹, yoshifumi Ohashi¹, Yasumori Sobue², Ryo Sato¹, Masataka Maeda¹, Hironobu Kosugiyama¹, yusuke Ohno¹, kenya terabe³, Shuji Asai¹ and Shiro Imagama¹, ¹Nagoya University Graduate School of Medicine, Nagoya, Japan, ²Japanese Red Cross Nagoya Daiichi Hospital, Nagoya, Japan, ³Nagoya University, Nagoya, Japan
Background/Purpose: The Boolean remission criteria proposed by the The American College of Rheumatology (ACR) and the European College of Rheumatology (EULAR) in 2011 are widely…
Abstract Number: 0428 • ACR Convergence 2023
Real World Patterns of Advanced Therapy Tapering in Early Rheumatoid Arthritis: Data from the Canadian Early Arthritis Cohort
Maria Powell¹, Vivian Bykerk², Orit Schieir³, Marie-France Valois⁴, Susan Bartlett⁵, Louis Bessette⁶, Gilles Boire⁷, Carol Hitchon⁸, Edward Keystone⁹, Janet Pope¹⁰, Carter Thorne¹¹, Diane Tin¹², Glen Hazlewood¹ and Canadian Early Arthritis Cohort (CATCH) Investigators¹³, ¹University of Calgary, Calgary, AB, Canada, ²Hospital for Special Surgery, New York, NY, ³McGill University, Montréal, QC, Canada, ⁴McGill University, Pointe-Claire, QC, Canada, ⁵McGill University, Montreal, QC, Canada, ⁶Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec City, QC, Canada, ⁷Université de Sherbrooke, Sherbrooke, QC, Canada, ⁸University of Manitoba, Manitoba, MB, Canada, ⁹Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ¹⁰University of Western Ontario, London, ON, Canada, ¹¹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²Centre of Arthritis Excellence, Newmarket, ON, Canada, ¹³CATCH, Toronto, ON, Canada
Background/Purpose: Recent Canadian treatment recommendations suggest offering to taper of biologic or targeted synthetic therapy to patients with rheumatoid arthritis (RA) after they achieve sustained…
Abstract Number: 0445 • ACR Convergence 2023
Comparison of the Efficacy, Safety and Immunogenicity of a Proposed Biosimilar MSB11456 with Tocilizumab Reference Product in Moderate-to-severe Rheumatoid Arthritis: Results of a Randomized Double-blind Study
Anna Zubrzycka-Sienkiewicz¹, Maria Misterska-Skora², Małgorzata Socik Pojawa³, Kamilla Klama⁴, Martin Ullmann⁵, Corinne Petit-Frere⁵, Andras Illes⁵, Peter Baker⁵, Joëlle Monnet⁵ and Jan Brzezicki⁶, ¹Reumatika - Centrum Reumatologil, Warsaw, Poland, ²Centrum Medyczne Oporów, Wrocław, Poland, ³MICS Centrum Medyczne Warszawa, Warsaw, Poland, ⁴Solumed Centrum Medyczne, Poznań, Poland, ⁵Fresenius Kabi SwissBiosimilars, Eysins, Switzerland, ⁶Centrum Kliniczno Badawcze, Elbląg, Poland
Background/Purpose: Tocilizumab is an anti‑interleukin‑6 receptor monoclonal antibody indicated for treating rheumatoid arthritis (RA) and other inflammatory diseases. MSB11456 is a proposed biosimilar to US‑licensed…
Abstract Number: 0473 • ACR Convergence 2023
The Number of Rheumatoid Arthritis Patients Who Give up Pregnancy Due to the Disease Is Decreasing
Ryo Inoue¹, Sakiko Isojima¹, Toshihiro Matsui², Shigeto Tohma³ and Nobuyuki Yajima⁴, ¹Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Shinagawa City, Tokyo, Japan, ²NHO Sagamihara National Hospital, Kanagawa, Japan, ³NHO Tokyo National Hospital, Dallas, TX, ⁴Showa-Universtiy of Medicine, Tokyo, Japan
Background/Purpose: Biologics have been shown not to be a disruption in pregnancy, and the reproductive health care environment surrounding rheumatoid arthritis patients has improved significantly.…
Abstract Number: 0769 • ACR Convergence 2023
Development and Validation of a Combined Clinical and Genetic Risk Score for Interstitial Lung Disease in a Large, Multicenter, Prospective Rheumatoid Arthritis Cohort
Austin Wheeler¹, Joshua Baker², Yangyuna Yang¹, Punyasha Roul¹, K Wysham³, Grant Cannon⁴, Gary Kunkel⁵, Gail Kerr⁶, Dana Ascherman⁷, Paul Monach⁸, Andreas Reimold⁹, Jill Poole¹, Tony Merriman¹⁰, Ted R Mikuls¹¹ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pennsylvania, Philadelphia, PA, ³VA Puget Sound/University of Washington, Seattle, WA, ⁴University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁵University of Utah, Salt Lake City, UT, ⁶Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ⁷University of Pittsburgh, Pittsburgh, PA, ⁸VA Boston Healthcare System, Boston, MA, ⁹University of Texas Southwestern Medical Center, Dallas, TX, ¹⁰University of Alabama at Birmingham, Birmingham, AL, ¹¹Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is an extra-articular manifestation of RA that causes substantial morbidity and mortality. Although some clinical and genetic risk…
Abstract Number: 0808 • ACR Convergence 2023
Real-World Disease Monitoring Patterns in Rheumatoid Arthritis-Associated Interstitial Lung Disease in the Veterans Affairs Health Care System
Bryant England¹, Tate Johnson¹, Yangyuna Yang¹, Punyasha Roul¹, Daniel Hershberger¹, Brian Sauer², Grant Cannon³, Joshua Baker⁴ and Ted R Mikuls⁵, ¹University of Nebraska Medical Center, Omaha, NE, ²Salt Lake City VA/University of Utah, Salt Lake City, UT, ³University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: There are currently no clinical practice guidelines for monitoring RA-associated interstitial lung disease (RA-ILD). Pulmonary function tests (PFTs) and chest computed tomography (CT) imaging…
Abstract Number: 0976 • ACR Convergence 2023
Sarcopenia and All-Cause Mortality in US Adults with and Without Rheumatoid Arthritis
Qiping Xu and Xuanling Du, Mayo Clinic Health System, Mankato, MN
Background/Purpose: Sarcopenia, which refers to the loss of muscle strength and mass, has been linked to adverse health outcomes. Although several systemic reviews have reported…
Abstract Number: 1022 • ACR Convergence 2023
Lower Rates of Statin Therapy Initiation in Dermatomyositis/Polymyositis vs. Rheumatoid Arthritis Patients with Hyperlipidemia: A Multicenter USA-Based Study (2018-2023)
Joseph Fares¹, ross Summer¹ and Giorgos Loizidis², ¹The Jane and Leonard Korman Respiratory Institute, Thomas Jefferson University Hospital, Philadelphia, PA, ²Division of Rheumatology, Thomas Jefferson University Hospital, Philadelphia, PA
Background/Purpose: Despite the proven cardioprotective benefits of statin therapy in RA, concern for statin-associated muscle symptoms (SAMS) might deter clinicians from prescribing them to DM/PM…
Abstract Number: 1260 • ACR Convergence 2023
Optimal Approaches for Reducing Depressive Symptoms in Rheumatoid Arthritis Patients Based on Psychological Interventions: A Systematic Review and Network Meta-analysis
Zhang Lijuan and Wu Beiwen, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Background/Purpose: In recent years, numerous psychological interventions for rheumatoid arthritis (RA) patients have been developed. However, it remains unclear which psychological interventions are effective and…
Abstract Number: 1278 • ACR Convergence 2023
Nature and Severity of Activity Limitations According to the Health Assessment Questionnaire Disability Index in Patients with Rheumatoid Arthritis and Functional Disability
Manja van Wissen¹, Maaike gademan¹, Cornelia van den Ende², Max Teuwen¹, Wilfred Peter¹, Dirkjan van Schaardenburg³, Alfons den Broeder², Thea Vliet Vlieland⁴ and Salima van Weely¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Sint Maartenskliniek, Nijmegen, Netherlands, ³Reade, Amsterdam, Netherlands, ⁴Leids University Medical Center, Leiden, Netherlands
Background/Purpose: Not withstanding modern treatment, some Rheumatoid Arthritis (RA) patients have severe disability due to persistently high disease activity, joint destruction/deformities and/or comorbidities. Insight into…
Abstract Number: 1294 • ACR Convergence 2023
Patient Reported Outcome Measures for Rheumatoid Arthritis Disease Activity: Using Rasch Measurement Theory and Cognitive Interviewing to Achieve More Meaningful Measurement
Tim Pickles¹, Mike Horton², Karl Bang Christensen³, Rhiannon Phillips⁴, David Gillespie¹, Neil Mo⁵ and Ernest Choy⁶, ¹Cardiff University, Cardiff, United Kingdom, ²University of Leeds, Leeds, United Kingdom, ³University of Copenhagen, Copenhagen, Denmark, ⁴Cardiff Metropolitan University, Cardiff, United Kingdom, ⁵Swansea Bay University Health Board, Port Talbot, United Kingdom, ⁶Section of Rheumatology, Cardiff University, Cardiff, United Kingdom
Background/Purpose: Disease Activity (DA) monitoring is a standard of care in Rheumatoid Arthritis (RA). A systematic review of Patient Reported Outcome Measures (PROMs) for RA…
Abstract Number: 1310 • ACR Convergence 2023
Comparison of Two Methotrexate Initiation Strategies in Rheumatoid Arthritis in Current Practice
Paola Vidal-Montal¹, Alice Combier², Alexia STEELANDT², Marion THOMAS², Javier Narvaez³, Joan Miquel Nolla¹, Yannick ALLANORE⁴ and Jerome AVOUAC⁵, ¹Department of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ²HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, ³Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴Université Paris Cité, Paris, France, ⁵Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France
Background/Purpose: To compare the efficacy and tolerance at 3 and 6 months of two methotrexate (MTX) initiation strategies in rheumatoid arthritis (RA). Methods: Retrospective,monocentric,cross-sectionalstudy including…
Abstract Number: 1327 • ACR Convergence 2023
Effects of Long-Term Low Dose Glucocorticoid Treatment for Rheumatoid Arthritis on Body Weight and Blood Pressure: A Pooled Analysis of Individual Patient Data from Five Randomised Trials
Andriko Palmowski¹, Sabrina Mai Nielsen², Zhivana Boyadzhieva³, Linda Hartman⁴, Judith Oldenkott⁵, Björn Svensson⁶, Ingiäld Hafström⁷, Siegfried Wassenberg⁸, Ernest Choy⁹, John Kirwan¹⁰, Robin Christensen¹¹, Maarten Boers¹² and Frank Buttgereit¹³, ¹Charité - Universitätsmedizin Berlin, Berlin, Germany, ²The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark, ³Charité Universitatsmedizine - Berlin, Berlin, Germany, ⁴Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁵Charite - University Medicine Berlin, Berlin, Germany, ⁶Lund University, Lund, Sweden, ⁷Karolinska Institutet, Stockholm, Sweden, ⁸Rheumazentrum Ratingen, Ratingen, Germany, ⁹Section of Rheumatology, Cardiff University, Cardiff, United Kingdom, ¹⁰University of Bristol, Bristol, United Kingdom, ¹¹Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen, Denmark, ¹²Amsterdam UMC, Vrije Universiteit, Amersfoort, Netherlands, ¹³Charité Universitätsmedizin, Dept. Rheumatology, Berlin, Germany
Background/Purpose: High-dose glucocorticoids (GCs) can cause weight gain and hypertension. It is unclear whether GCs at ≤7.5mg/day prednisone equivalent ("low dose"), administered for rheumatoid arthritis…
Abstract Number: 1343 • ACR Convergence 2023
Cardiovascular (CV) and Malignancy Events in the Filgotinib Rheumatoid Arthritis (RA) Clinical Development Program up to 8.3 Years
Xavier Mariette¹, Sven Borchmann², Sandrine Aspeslagh³, Jaime Calvo- Alén⁴, Richard Moriggl⁵, Zoltan Szekanecz⁶, Francesco De Leonardis⁷, Nadia Verbruggen⁸, Paul Van Hoek⁹, Marc Schmalzing¹⁰, Andreas Stallmach¹¹, Christina Charles-Schoeman¹², Vijay Rajendran¹³, Christine Rudolph⁹, Chris Watson¹⁴, Yoshiya Tanaka¹⁵ and Ernest Choy¹⁶, ¹Université Paris-Saclay, Le Kremlin-Bicêtre, France, ²Department of Internal Medicine, University of Cologne, Cologne, Germany, ³Department of Medical Oncology, UZ Brussel, Brussels, Belgium, ⁴Rheumatology, Bioaraba Research Unit, Hospital Universitario Araba, Vitoria, Spain, ⁵Institute of Animal Breeding and Genetics, University of Veterinary Medicine, Vienna, Austria, ⁶Division of Rheumatology, University of Debrecen, Debrecen, Hungary, ⁷Medical Affairs, Galapagos GmbH, Basel, Switzerland, ⁸Biostatistics, Galapagos NV, Mechelen, Belgium, ⁹Medical Safety, Galapagos NV, Mechelen, Belgium, ¹⁰University Hospital, Rheumatology/Clinical Immunology, Department of Internal Medicine II, Würzburg, Germany, ¹¹Department of Internal Medicine, Jena University Hospital, Jena, Germany, ¹²UCLA Medical Center, Santa Monica, CA, ¹³Clinical Research, Galapagos NV, Mechelen, Belgium, ¹⁴Medical Affairs, Galapagos Biotech Ltd., Cambridge, United Kingdom, ¹⁵University of Occupational and Environmental Health, Kitakyushu, Japan, ¹⁶Section of Rheumatology, Cardiff University, Cardiff, United Kingdom
Background/Purpose: Filgotinib (FIL) is a Janus kinase (JAK) 1 preferential inhibitor for the treatment of RA. Data from the ORAL Surveillance post-marketing study (NCT02092467) suggest…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].